BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 26199168)

  • 1. Self-report and Clinical Response to Peyronie's Disease Treatment: Peyronie's Disease Questionnaire Results From 2 Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies.
    Hellstrom WJ; Feldman RA; Coyne KS; Kaufman GJ; Smith TM; Tursi JP; Rosen RC
    Urology; 2015 Aug; 86(2):291-8. PubMed ID: 26199168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease.
    Gelbard M; Hellstrom WJ; McMahon CG; Levine LA; Smith T; Tursi J; Kaufman G; Goldstein I
    J Sex Med; 2013 Nov; 10(11):2822-31. PubMed ID: 24112401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies.
    Lipshultz LI; Goldstein I; Seftel AD; Kaufman GJ; Smith TM; Tursi JP; Burnett AL
    BJU Int; 2015 Oct; 116(4):650-6. PubMed ID: 25711400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire.
    Hellstrom WJ; Feldman R; Rosen RC; Smith T; Kaufman G; Tursi J
    J Urol; 2013 Aug; 190(2):627-34. PubMed ID: 23376705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.
    Cocci A; Cito G; Urzì D; Minervini A; Di Maida F; Sessa F; Mari A; Campi R; Falcone M; Capece M; Morelli G; Cacciamani G; Rizzo M; Polito C; Giammusso B; Morgia G; Verze P; Salonia A; Cai T; Mirone V; Mondaini N; Russo GI
    J Sex Med; 2018 Oct; 15(10):1472-1477. PubMed ID: 30245025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study.
    Cocci A; Russo GI; Salonia A; Cito G; Regis F; Polloni G; Giubilei G; Cacciamani G; Capece M; Falcone M; Greco I; Timpano M; Minervini A; Gacci M; Cai T; Garaffa G; Giammusso B; Arcaniolo D; Mirone V; Mondaini N
    J Sex Med; 2018 May; 15(5):716-721. PubMed ID: 29699756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.
    Levine LA; Cuzin B; Mark S; Gelbard MK; Jones NA; Liu G; Kaufman GJ; Tursi JP; Ralph DJ
    J Sex Med; 2015 Jan; 12(1):248-58. PubMed ID: 25388099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's Disease.
    Goldstein I; Lipshultz LI; McLane M; Hu Y; Xiang Q; Liu G; Vijayan S; Gelbard MK
    J Urol; 2020 Jun; 203(6):1191-1197. PubMed ID: 31922462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responsiveness of the Peyronie's Disease Questionnaire (PDQ).
    Coyne KS; Currie BM; Thompson CL; Smith TM
    J Sex Med; 2015 Apr; 12(4):1072-9. PubMed ID: 25664497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Peyronie's Disease With Collagenase Clostridium histolyticum and Vacuum Therapy: A Randomized, Open-Label Pilot Study.
    Ralph DJ; Abdel Raheem A; Liu G
    J Sex Med; 2017 Nov; 14(11):1430-1437. PubMed ID: 28974406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease.
    Serefoglu EC; Smith TM; Kaufman GJ; Liu G; Yafi FA; Hellstrom WJG
    Urology; 2017 Sep; 107():155-160. PubMed ID: 28554517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Collagenase Clostridium histolyticum (Xiapex
    Cocci A; Di Maida F; Russo GI; Capogrosso P; Francesco L; Rizzo M; Di Mauro M; Salonia A; Cito G; Falcone M; Romano A; Polloni G; Martinez-Salamanca JI; Fernández-Pascual E; Minervini A; Mondaini N
    Clin Drug Investig; 2020 Jun; 40(6):583-588. PubMed ID: 32342279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.
    Gelbard M; Goldstein I; Hellstrom WJ; McMahon CG; Smith T; Tursi J; Jones N; Kaufman GJ; Carson CC
    J Urol; 2013 Jul; 190(1):199-207. PubMed ID: 23376148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.
    Yang KK; Bennett N
    Urology; 2016 Aug; 94():143-7. PubMed ID: 27211926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners.
    Goldstein I; Knoll LD; Lipshultz LI; Smith T; Kaufman GJ; McMahon CG
    Sex Med; 2017 Jun; 5(2):e124-e130. PubMed ID: 28395998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment.
    Levine LA; Larsen SM
    J Sex Med; 2015 Jan; 12(1):259-64. PubMed ID: 25345351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient perspectives on Peyronie's disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum.
    Kaminetsky J; Gittelman M; Kaufman GJ; Smith TM; Jordan GH
    Int J Impot Res; 2019 Jul; 31(4):263-268. PubMed ID: 30237548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.
    Abdel Raheem A; Capece M; Kalejaiye O; Abdel-Raheem T; Falcone M; Johnson M; Ralph OG; Garaffa G; Christopher AN; Ralph DJ
    BJU Int; 2017 Nov; 120(5):717-723. PubMed ID: 28612401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis.
    Hellstrom WJG; Tue Nguyen HM; Alzweri L; Chung A; Virasoro R; Tapscott A; Ziegelmann M; Trost L; Gelbard M
    J Urol; 2019 Apr; 201(4):777-782. PubMed ID: 30672843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease.
    Abdel Raheem A; Johnson M; Ralph D; Garaffa G
    Minerva Urol Nefrol; 2018 Aug; 70(4):380-385. PubMed ID: 29761688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.